PHARMIA’s leadership team is comprised of individuals who are dedicated in upholding the company’s core principles of quality, affordability, and integrity. We will produce and sell products with the highest quality we expect for ourselves, our children and our friends, and sell them at the lowest possible margin we can rationally provide to patients, payers, and our healthcare system. This is our key driving principle for the formation of the company and its ongoing operations. Based on a solid starting foundation and a low risk business model, the investors should have full confidence in Dr. Sinkule, Dr. Hirschman, and the US and European management team’s ability to work together, complimenting each other, in a manner to help further the vision and strategy to cooperatively bring the Company into the next 3 Stages of commercial operation.
Our dedicated team is comprised of individuals with the technical, pharmaceutical manufacturing, clinical and business expertise that is necessary for innovation that results in the development of a diverse range of life-saving medicines. PHARMIA personnel and advisors in the U.S. and Europe have extensive experience in the “branded” pharmaceutical and the generic drug industries, and in biotechnology and biosimilar processes for making and selling biologic drugs. The Company will exploit its technical and commercial expertise to develop and obtain approval to launch, market and sell our own branded, onco-generic and super-generic product lines while also offering significant cost savings to patients, doctors, and payers – both in Government and Private practice.